After obtaining a PhD degree in the University of Paris VII in 1993, Dominique Bonnet joined as a research fellow the group of Professor John Dick's laboratory in Toronto, Canada. In 1998, she accepted a position as Group Leader at the Coriell Institute for Medical Research, in New Jersey and became Assistant Professor, University of Medicine and Dentistry of New Jersey. In 2001, she moved to London at the Imperial Cancer Research Fund (ICRF; which became Cancer Research UK in 2002). In 2006, she became a Senior Group Leader at the London Research Institute (now part of the Francis Crick Institute). Since August 2002, she is also Professor at the University College of London, division of Biosciences, and a Senior Lecturer at the Institute of Child Health.
Dominique Bonnet is interested in understanding the regulation of the haematopoietic stem cells, both in normal development and during leukaemia. The laboratory is interested in studying both normal human haematopoietic stem cells (HSCs) and leukaemic stem cells (LSCs).
Dr. Ming Lei is a molecular geneticist by training. He earned his PhD degree from Cornell University and continued his postdoctoral training there. He was a faculty member at the Medical College of Wisconsin, where he taught Genetics and Microbiology to medical students and graduate students. He was a NIH funded principal investigator focusing his research efforts on the regulation of eukaryotic DNA replication. He began his governmental service in 2006 at the National Science Foundation, where he managed NSF’s research grant portfolio in Molecular Biology, Genetics and Genomics. He has been with the National Cancer Institute since 2008.
Dean Tang, PhD, was trained as a Pathologist and is currently Professor & Chair in Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. His Master of Science thesis research (1986-1989), conducted in Dr. Hong-shen Tian’s laboratory in Wuhan University School of Medicine, focused on establishing lung cancer metastasis models. To continue his research on metastasis, Dr. Tang joined Dr. Ken Honn’s lab at Wayne State University (WSU) in 1989 to study the role of integrin receptors in mediating tumor cell – extracellular matrix interactions, tumor cell invasion, and tumor cell extravasation. Dr. Tang obtained his PhD in Cancer Biology in 1994 and stayed at WSU for a few years to explore apoptosis-based anti-prostate cancer therapeutics. In 1998, he was awarded a Burroughs-Wellcome Hitchings-Elion post-doctoral Fellowship to study oligodendrocyte precursor cell (OPC) development in Dr. Martin Raff’s lab in Medical Research Council (MRC) Laboratory for Molecular & Cellular Biology (LMCB) of University College London (UCL, UK). Dr. Tang returned to America in June of 2000 to join the MD Anderson Cancer Center Department of Epigenetics and Molecular Carcinogenesis till May of 2016.
Dr. Tang and his colleagues have been studying cancer stem cells and cancer cell heterogeneity with a focus on prostate cancer. His career goals are to identify novel therapeutics and therapeutic combinations for personalized cancer treatment.
Thierry Virolle is a Research Director (permanent position) at Institut National de la Santé et de la Recherche Médicale (INSERM), Head of the Team Cancer Stem Cell Plasticity and Functional intra-tumor Heterogeneity at the Institute of Biologie Valrose (iBV). He is Co-Founder of the French National Sud Cancer Stem Cell Network, SUNRiSE dedicated to the study of cancer stem cell.
He is Doctor of Science (PhD) at Nice Sophia Antipolis University (2000), his researches focus on the regulation of the plasticity of glioblastoma cancer stem cells and its contribution in the genesis of functionally divergent tumor territories.
Emmanuelle Charafe-Jauffret is a doctor of medicine and a specialist in breast cancer, and is known for her expertise in cancer stem cells.
She led a group on the characterization of cancer stem cells in the gland breast.
Dr. Qien Wang is an Associatet Professor in the Department of Radiology and Comprehensive Cancer Center at the Ohio State University. Dr. Wang received his Bachelor Degree in Preventive Medicine in Shanxi Medical College in 1992, and obtained his PhD from Beijing Medical University in 1997 in China. Then, Dr. Wang worked as a Lecturer and Associate Professor at Peking University Medical Center for 4 years. During this time, his research was focused on understanding how gene and environmental exposure interact in carcinogenesis. In 2001, Dr. Wang joined Dr. Altaf Wani’s laboratory at the Ohio State University in the United States of America to study the mechanism of DNA repair as a Research Associate and Research Scientist. Since 2011, Dr. Wang has become a Tenure-track Assistant Professor at the Ohio State University, and was promoted to Associate Professor with Tenure in 2017.
Dr. Wang’s research is focused on a mechanistic understanding of cancer progression, metastasis and recurrence, particularly in term of cancer stem cells.
Dr. Ralf Huss joined Definiens in 2013 and has more than 20 years of training and experience in histopathology and cancer research. Dr. Huss also co-founded the biotech company APCETH. He has published more than 100 papers, and has worked with the Nobel Laureates Rolf Zinkernagel and E. Donnell Thomas.
He has training and experience in immunology, transplantation biology and stem cell research and also involved in identifying new tissue biomarkers to stratify cancer patients.
Hervé Chneiweiss, first trained as a neurologist (movement disorders, Parkinson), HC was involved in the neurogenetics of human diseases such as cerebellar ataxias. For the last 15 years his scientific work was dedicated to the biology of astrocytes and their roles in brain tumor progression. He created in 2006 the Inserm laboratory U752, which gathered scientists and clinicians devoted to the study of brain tumors. HC is since 2014 director of the laboratory Neuroscience Paris Seine.
Hervé Chneiweiss is studying molecular mechanisms involved in glial plasticity and underlying brain tumor development. Privileged technical expertise includes proteomics and cell cultures. Hervé Chneiweiss is also involved in bioethics and editor of Medecine/Sciences
After graduating from the Royal College of Surgeons in Ireland in 2004 with a PhD in Oncology, Stephen Maher spent 3 years as a visiting fellow at the National Cancer Institute in the US. In 2007 he returned to Ireland and Trinity College Dublin, St. James’s Hospital as a research fellow. In 2010 he established his own research group having secured an Irish Cancer Society Fellowship and a number of Health Research Board grants, predominantly in the area of radiation resistance in the treatment of gastrointestinal malignancy. In 2012 Stephen moved to the University of Hull and Hull York Medical School as a senior lecturer, where he led the Cancer Biology and Therapeutics lab. In 2016 Stephen returned to Trinity College Dublin as the James Ussher Assistant Professor in Translational Oncology, where he has set up new cancer radiobiology and hypoxia research cores.
At the Department of Surgery, based at TCD and St. James’s Hospital Dublin, Stephen is primarily interested in understanding the complex molecular mechanisms underpinning resistance to radiotherapy and chemotherapy in oesophageal adenocarcinoma and malignant pleural mesothelioma. He is currently examining the role of microRNAs and cancer stems cells in driving resistance to treatment, and researching microRNA replacement therapy as a novel therapeutic to augment patient responses to conventional cytotoxics.
Dr. Subhra Mohapatra has completed her PhD from University of Manitoba, Canada and postdoctoral studies at H. Lee Moffitt Cancer Center. Currently, she is an Associate Professor of Molecular Medicine in the Morsani College of Medicine, University of South Florida. During last 10 years, she has trained 13 postdocs and 16 graduate students involved in multidisciplinary research, such as biology, immunology, nanoscience and nanotechnology fields. She has authored over 62 scientific papers and holds 12 US patents. Her research is funded by the National Institute of Health, Veterans Administration and Florida Department of Health. She has been serving as an Academic Editor for the Plos One.
Our research is focused on understanding the role of stromal cells in the tumor microenvironment that play a critical role in tumor growth and recurrence. We use nanotechnology–integrated cellular and molecular approaches to dissect major signaling pathways in cancers and identify novel drug targets and biomarkers and experimental therapeutics for cancer. We have also synthesized 3D/4D polymeric nano/micro scaffolds for studying tumor-stroma interactions in modulating cancer stem cell expansion and anticancer drug targets. We are also investigating the mechanism of anti-inflammatory triggers for traumatic brain injury.